BASF's new bioactive ingredient the wellness elixir for healthy skin
The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.
Extracted from the chaga mushroom (Inonotus obliquus), native to the Northern Canadian forest, Inolixir is the most recent addition to BASF’s portfolio of bioactive ingredients. With its antioxidant and anti-inflammatory properties, it fortifies the skin’s natural protection system by strengthening barrier function and the microvascular network – working on all fronts to return skin to a healthier condition, with visible results on fine lines, dark-circles and redness.
A superfood ingredient for healthy skin
The chaga mushroom is a superfood renowned for various health benefits and has both traditional and modern uses. With Inolixir (INCI: Glycerin (and) Water (and) Inonotus Obliquus (Mushroom) Extract), BASF scientists have now harnessed the chaga mushroom’s power for use in skin care products, catering to the worldwide consumer trend of changing perceptions of beauty and the increasing popularity of a more holistic approach. This often involves consumers making lifestyle changes and, importantly, looking for cosmetic products with natural ingredients.
A powerful, dual action bioactive ingredient offering quick and long-lasting results
Inolixir works in two ways: first, it offers a wellness approach proven to be effective on tired and stressed skin. Study participants reported that Inolixir was as effective as a 5-day relaxation cure in mitigating fatigue lines, dark circles and dullness. Second, the bioactive ingredient presents dermocosmetic solutions for sensitive skin: it offers anti-redness and anti-dullness benefits, leading 85% of study participants to perceive a health benefit for their skin and 91% to report increased skin comfort within 7 to 28 days of application.
Inolixir is a hyper-concentrated bioactive ingredient, benefitting from all the nutrients and properties of the chaga mushroom thanks to an innovative and eco-friendly technology: subcritical water extraction (SWE). Instead of organic solvents, this method uses pressurized water heated to between 100 °C and 374 °C for extraction. In vitro tests have proven that SWE extracts phytochemicals more efficiently than other common methods, such as conventional hydroethanolic extraction and water extraction.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance